630 results on '"Valentino, L. A."'
Search Results
102. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE)
103. Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond
104. Healthcare resource utilization among haemophilia A patients in the United States
105. Exploring the biological basis of haemophilic joint disease: experimental studies
106. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
107. High prevalence of thyroid dysfunction in adult patients with β-thalassemia major submitted to amiodarone treatment
108. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease
109. An uncommon cause of knee haemarthrosis in an adult haemophilia patient suffering from long-term paraplegia
110. Joint protection in haemophilia
111. Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX
112. Assessment of blood-induced arthritis causes friction
113. Make ours marvel: media convergence and a comics universe
114. ‘My claim to fame is footnotes’: an interview with Derf Backderf
115. P171 Catastrophic systemic multiple embolism from a giant atrial mixoma: a case report
116. Towards the evaluation of defects in MoS2 using cryogenic photoluminescence spectroscopy
117. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice
118. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy
119. Patient/caregiver-reported bleed symptoms and reasons for starting/stopping treatment with recombinant factor VIIa (rFVIIa): analysis of the dosing observational study in hemophilia (DOSE): 17P72
120. Healthcare resource utilization among hemophilia A patients with inhibitor status in the US: 14P09
121. Stability and predictability of treatment cost among non-inhibitor hemophilia patients in the US: 14P10
122. Session S2.4 Safety and prolonged biological activity following a single administration of a recombinant molecular fusion of native human coagulation factor IX and the Fc region of immunoglobulin G (IgG) (rFIXFc) to subjects with hemophilia B: 07FP07
123. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors
124. Selective self-assembly and light emission tuning of layered hybrid perovskites on patterned graphene
125. Controversies regarding the prophylactic management of adults with severe haemophilia A
126. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices
127. The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report
128. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series
129. Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A
130. Prevention of haemarthrosis in a murine model of acute joint bleeding
131. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors
132. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes
133. Physiopathology of haemophilic arthropathy
134. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice
135. The impact of joint bleeding and synovitis on physical ability and joint function in a murine model of haemophilic synovitis
136. Queer Theory
137. Optimizing outcomes for patients with severe haemophilia A
138. Arthroscopic synovectomy in haemophilia: indications, technique and results
139. Prophylaxis and treatment of chronic synovitis in haemophilia patients with inhibitors
140. Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage
141. Pathogenesis of haemophilic synovitis: clinical aspects
142. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA®) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors
143. Reformulated BENEFIX®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B
144. Arresting development: comics at the boundaries of literature
145. Implications of TiO2 surface functionalization on polycrystalline mixed halide perovskite films and photovoltaic devices
146. FEIBA prophylaxis for patients with haemophilia and inhibitors
147. Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis
148. Surgical excision of a giant pelvic pseudotumour in a patient with haemophilia A
149. Von Willebrand factor/factor VIII concentrate (Humate-P) for surgical prophylaxis of excessive bleeding in patients with severe von Willebrand disease (vWD): 30 PO 898
150. FEIBA prophylaxis is cost effective for the pediatric patient: 14 PO 430
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.